This study will compare two different dosing methods of azathioprine (IMURAN) in participants
with Crohn's disease who are currently taking steroids (e.g. prednisone or budesonide)or who
have just started steroids. The study can be up to 54 weeks long. All participants enrolled
will receive active drug. Participants will take doses either based upon weight or based on
the patient's ability to breakdown the drug (monitored by 6-thioguanine nucleotides (6-TGN)
metabolite levels in the blood). All patients enrolled in the study will receive active study
drug.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)